[Federal Register Volume 83, Number 28 (Friday, February 9, 2018)]
[Notices]
[Page 5809]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-02638]



[[Page 5809]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: 
Cerilliant Corporation

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before April 10, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DRW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.33(a), this is notice that on July 
19, 2017, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round 
Rock, Texas 78665-2402 applied to be registered as a bulk manufacturer 
of the following basic classes of controlled substances:

------------------------------------------------------------------------
           Controlled substance               Drug code       Schedule
------------------------------------------------------------------------
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-             7010  I
 oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-
 indazole-3-carboxamide).
MDMB-FUBINACA (Methyl 2-(1-(4-                       7020  I
 fluorobenzyl)-1H-indazole-3-carboxamido)-
 3,3-dimethylbutanoate).
MAB-CHMINACA (N-(1-amino-3,3dimethyl-1-              7032  I
 oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-
 indazole-3-carboxamide).
5F-AMB (Methyl 2-(1-(5-fluoropentyl)-1H-             7033  I
 indazole-3-carboxamido)-3-
 methylbutanoate).
5F-ADB; 5F-MDMB-PINACA (Methyl 2-(1-(5-              7034  I
 fluoropentyl)-1H-indazole-3-carboxamido)-
 3,3-dimethylbutanoate).
MDMB-CHMICA, MMB-CHMINACA (Methyl 2-(1-              7042  I
 (cyclohexylmethyl)-1H-indole-3-
 carboxamido)-3,3-dimethylbutanoate).
5F-APINACA, 5F-AKB48 (N-(adamantan-1-yl)-            7049  I
 1-(5-fluoropentyl)-1H-indazole-3-
 carboxamide).
U-47700 (3,4-dichloro-N-[2-                          9547  I
 (dimethylamino)cyclohexyl]-N-
 methylbenzamide).
Acryl fentanyl (N-(1-phenethylpiperidin-4-           9811  I
 yl)-N-phenylacrylamide).
4-Fluoroisobutyryl fentanyl (N-(4-                   9824  I
 fluorophenyl)-N-(1-phenethylpiperidin-4-
 yl)isobutyramide).
Furanyl fentanyl (N-(1-phenethylpiperidin-           9834  I
 4-yl)-N-phenylfuran-2-carboxamide).
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances to make reference standards which will be 
distributed to its customers.

    Dated: January 31, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
[FR Doc. 2018-02638 Filed 2-8-18; 8:45 am]
 BILLING CODE 4410-09-P